NasdaqGM:BCAXBiotechs
Bicara Therapeutics (BCAX) Is Up 13.5% After Breakthrough Status And Equity Raise Strengthen Cash Runway – Has The Bull Case Changed?
Bicara Therapeutics Inc. has reported 2025 results showing a higher net loss of US$137.95 million while simultaneously bolstering its balance sheet through an oversubscribed public offering and filing a US$70.36 million shelf registration for additional common stock.
Against this backdrop, the company’s lead candidate ficerafusp alfa secured FDA Breakthrough Therapy Designation and advanced into a pivotal Phase III trial, prompting renewed attention to how Bicara is balancing heavier losses...